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eativecommons.org/licenses/by-nc-Summary Background and aim: Barrett’s esophagus (BE) is the most common cause or pre-
cursor of esophageal adenocarcinoma (EAC), a condition with a poor prognosis. This study
aimed to investigate the clinical characteristics and risk of EAC in patients with BE.
Materials and methods: From January 2001 to December 2012, a total of 425 patients with
histologically proven BE were identified and analyzed retrospectively. Patients’ personal data
(smoking, alcohol consumption), underlying systemic disease data (diabetes mellitus and hy-
pertension), endoscopic findings (hiatal hernia, peptic ulcer, endoscopically suspected
esophageal metaplasia, severity of reflux esophagitis, rapid urease test), and pathological
findings (degree of dysplasia, Helicobacter pylori infection) were collected for further
analysis.
Results: In this retrospective study, 15 patients were diagnosed with EAC. Only one patient
was found to have EAC during endoscopic surveillance for BE. The majority of patients
(14/15 patients) suffered alarm symptoms and were diagnosed to have BE and EAC concur-
rently. Meanwhile, EAC is already relatively at an advanced stage. The mean age for diagnosis
of EAC in a patient with BE was 67.67  9.92 years old. All patients were male. From a total
of 15 patients, 33.3% (5 patients) demonstrated erosive esophagitis under endoscopy and 60%
(3 of 5 patients) of these were classified as Los Angeles grade C or D disease.
Conclusion: Our study found that BE-associated EAC mostly occurred in older men. In the
group with BE-associated EAC, the majority of patients were discovered due to alarmt of Gastroenterology and Hepatology, Chang Gung Memorial Hospital, Number 5 Fu-Hsin Street,
33, Taiwan.
.org.tw (C.-T. Chiu).
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136 H.-W. Wang et al.symptoms, at the same time as esophageal adenocarcinoma had already developed. Further
prospective study is needed to stratify the risk of disease progression in BE patients.
Copyright ª 2015, The Gastroenterological Society of Taiwan, The Digestive Endoscopy Soci-
ety of Taiwan and Taiwan Association for the Study of the Liver. Published by Elsevier Taiwan
LLC. This is an open access article under the CC BY-NC-ND license (http://creativecommons.
org/licenses/by-nc-nd/4.0/).Introduction
Barrett’s esophagus (BE) is the most common cause or
precursor of esophageal adenocarcinoma (EAC) and has a
poor prognosis. The overall risk of cancer developing in BE
patients is estimated to be approximately 0.12e0.5% per
year [1e4]. The prognosis is linked strongly to the stage of
the tumor at the time of detection. The 5-year survival rate
can be as high as 83e90% in the early stages, compared with
only 10e15% in late-stage cancers [5e7]. Chronic esopha-
geal acid exposure, being male, old age, visceral obesity,
hiatus hernia, smoking, and alcohol consumption are risk
factors for BE in Asia. Helicobacter pylori infection showed
a protective effect on BE [8]. In Western countries, BE has
been diagnosed in approximately 10e15% of patients un-
dergoing an endoscopy for gastroesophageal reflux disease
(GERD) symptoms [1]. Although GERD is less prevalent in
Asia than in the West, its incidence is rapidly rising in Asia
due to the change to Western-style eating habits [9]. EAC
has increased progressively with an increased prevalence of
GERD in Western countries; whereas in Asia, despite the
increased prevalence of GERD, EAC has not increased
accordingly [8,10]. However, esophageal squamous cell
carcinoma is still the dominant cell type of esophageal
cancer in Asian countries. Our retrospective study aimed to
investigate the clinical characteristics and risk of EAC in
patients with BE in Taiwan.
Materials and methods
Patient selection
A total of 425 patients, first diagnosed with BE histopath-
ologically between 2001 and 2012, were identified retro-
spectively by reviewing pathological reports at Chang Gung
Memorial Hospital, Linkou, Taiwan. These patients were
analyzed using personal characteristics, including age, sex,
smoking and alcohol usage, underlying systemic disease
(diabetes mellitus and hypertension), and indications from
endoscopic examination; endoscopic findings (hiatal her-
nia, peptic ulcers, severity of reflux esophagitis, rapid
urease test, and endoscopically suspected esophageal
metaplasia); and, pathological findings (degree of
dysplasia, H. pylori infection). Rapid urease test was used
to determine the presence of H pylori and it depended on
clinical indication. However, not all BE patients received
the rapid urease test in this retrospective study. The pa-
tients were then analyzed using the above information to
identify the risks for EAC in the Barrett’s population. This
study was carried out with preapproval by the Linkou
Chang-Gung Memorial Hospital Institutional Review Board
(102-2699B).Endoscopy and definition of BE
Indications of the endoscopies were collected from the de-
scriptions on the endoscopic official reports and comprised
the typical reflux symptoms (including acid regurgitation and
heart burn), abdominal pain, asymptomatic or surveillance
of BE, gastrointestinal (GI) tract bleeding, chest pain,
dysphagia, and other causes. Reflux esophagitis was diag-
nosed using endoscopy and classified into grades AeD using
the Los Angeles (LA) classification [11,12]. Endoscopically
suspected esophageal metaplasia (ESEM) was defined as a
length of columnar epithelium that extended continuously
from the gastric lumen to the esophagus and was recorded
using Prague Barrett’s C(circumferential) & M(maximal
extent) criteria [13]. The length of BE was not measured
using Prague Barrett’s C & M criteria prior to 2006. The
definition of BE using pathological criteria requires that in-
testinal metaplasia with goblet cells is present in the
esophageal columnar-lined mucosa of the esophagus.
Statistical analysis
We performed statistical analyses on the acquired data
using SPSS version 20.0(Armonk, NY: IBM Corp). Nine vari-
ables, including sex, age, indication of esophagogas-
troduodenoscopy (EGD), smoking history, alcohol use,
hiatal hernia, the presence of erosive esophagitis, and un-
derlying diseases (diabetes and hypertension) were
considered as potential risk factors for adenocarcinoma
among the BE patients. Quantitative data were reported as
means and standard deviation, whereas categorical data
were expressed as proportions.
The data were analyzed using the Student t test for
continuous variables, and Chi-square test for categorical
variables.
Univariate analysis was performed to assess the effect of
each variable. Logistic regression was used to identify in-
dividual correlations associated with adenocarcinoma risk.
Using the backward stepwise method, variables with a p
value < 0.05 were included in the multivariate logistic
regression models. Odds ratios (ORs) and 95% confidence
intervals (CIs) were estimated where appropriate. A two-
sided p value < 0.05 was considered to be significant in
all statistical tests.
Results
Barrett’s population
In the total study population, 313 patients (73.6%) were
males with a mean age of 57.04 17.38 years, and themale-
to-female ratio was 2.8:1. Adenocarcinomawas diagnosed in
Figure 1 Esophagogastroduodenoscopy (EGD) indications in
the study patients (n Z 425).
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67.67  9.92 years. Patient characteristics are shown in
Table 1. Indications for endoscopic examination (Fig. 1)
included typical reflux symptoms (acid regurgitation and
heart burn) in 231 (54.4%) patients, asymptomatic or
endoscopy followed up in 55 (12.9%) patients, abdominal
pain in 40 (9.4%) patients, GI tract bleeding in 36 (8.5%) pa-
tients, dysphagia in 22 (5.2%) patients, chest pain in 25
(5.9%) patients, and other causes in 16 (3.8%) patients.
Endoscopic findings
Among the 425 patients with BE, 271 (63.8%) patients were
diagnosed with reflux esophagitis, and according to the LA
classification system 133 (31.3%) patients were classified as
grade A, 83 (19.5%) patients as grade B, 26 (6.1%) patients
as grade C, and 29 (6.8%) patients as grade D. There were
49 of 94 patients (52.1%) who recorded a positive finding on
the H. pylori test and 124 of 425 patients (29.2%) who had a
hiatal hernia. We analyzed the endoscopic findings of BE
cases according to the Prague criteria which was published
on 2006. The mean length of the circumferential extent was
2.08 cm (range: 0e9 cm) and the mean length of the
maximal extent was 3.67 cm (range: 1e10 cm). There are a
total of 83 BE cases classified by Prague C & M criteria in our
study group. According to the C & M criteria, 43 cases can
be classified as short segment and 40 cases as long segment.
Pathological findings
In the initial biopsy specimens, nine patients (2.1%) were
found to have dysplastic mucosa, eight patients had low-
grade dysplasia, and one patient had high-grade dysplasia.Table 1 Clinical characteristics of the study groups.
Total (n Z 425) BE (n Z
Male (%) 313 (73.6) 298 (72
Age (y), mean  SD 57.04  17.38 56.65 
EGD indication
Heartburn/regurgitation (%) 231 (54.4) 225 (54
Asymptomatic (%) 55 (12.9) 55 (13.
Abdominal pain (%) 40 (9.4) 40 (9.8
GI bleeding (%) 36 (8.5) 33 (8.0
Chest pain (%) 25 (5.9) 25 (6.1
Dysphagia (%) 22 (5.2) 16 (3.9
Reflux esophagitis
Yes (%) 271 (63.8) 266 (64
Grade A (%) 133 (31.3) 132 (32
Grade B (%) 83 (19.5) 82 (20)
Grade C (%) 26 (6.1) 26 (6.3
Grade D (%) 29 (6.8) 26 (6.3
Hiatal hernia (%) 124 (29.2) 121 (29
Helicobacter pylori (%) 49/94 (52.1) 48/93
Smoking (%) 144 (33.9) 139 (33
Alcohol (%) 84 (19.8) 78 (19.
Diabetes mellitus (%) 70 (16.5) 67 (16.
Hypertension (%) 132 (31.1) 128 (31
*p value is significant using Chi-square test.
BEZ Barrett’s esophagus; EGD Z esophagogastroduodenoscopy; GI ZA total of 15 patients (3.5%) were diagnosed with adeno-
carcinoma in our study group, including one patient with
high-grade dysplasia initially, but patient was lost to follow
up. Esophageal adenocarcinoma developed 31 months
later.
The mean number of times and the duration of endo-
scopic surveillance for the low-grade dysplasia of BE were
1.9 times (1.9  1.1) and 9 months (9  9.3) without pro-
gression, respectively.
EAC in the BE population
A total of 15 patients with BE and EAC concurrently were
recorded in our study (Table 1). They were all male patients
with a mean age of 67.67  9.92 years. The majority (14/15
patients) were diagnosed with EAC at the first time of EGD.
One patient was under regular surveillance for BE with a
previous finding of reflux esophagitis LA grade D and high-
grade dysplasia. Indications for endoscopic examination410) BE with adenocarcinoma (n Z 15) p
.7) 15 (100) 0.018
17.49 67.67  9.92 0.009
.9) 6 (40) 0.256
4) 0 (0) 0.128
) 0 (0) 0.204
) 3 (20) 0.103
) 0 (0) 0.324
) 6 (40) <0.001
.9) 5 (33.3) 0.013
.2) 3 (20)
1 (6.7)
) 0 (0)
) 1 (6.7)
.5) 3 (20) 0.426
(51.6) 1/1 (100)
.9) 5 (33.3) 0.964
0) 6 (40) 0.045
3) 3 (20) 0.707
.5) 4 (26.7) 0.708
gastrointestinal; SD Z standard deviation.
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regurgitation (6/15 patients, 40%), and GI bleeding (3/15
patients, 20%). Endoscopic findings reported reflux esoph-
agitis (5/15 patients, 33.3%) including LA grade A and B (4/
15 patients, 26.7%) and LA grade C and D (1/15 patients,
6.7%). Hiatal hernia was noted in 20% of these patients (3/
15). Eight people received surgical resection and esopha-
geal reconstruction, depending on whether or not the le-
sions were involved with the cardia; two patients received
endoscopic mucosal resection; two patients received con-
current chemo-radiotherapy; and three patients were lost
to follow up.
In the Chi-square test analysis model (Table 1), male sex
(pZ 0.018), dysphagia as an indication of EGD (p < 0.001),
reflux esophagitis (p Z 0.013), and alcohol consumption
(p Z 0.045), and in the Student t test model age at diag-
nosis of BE (p Z 0.009) were identified as potential risk
factors for BE. An age of  57 years at diagnosis of BE was
associated with an AUROC (Area Under the Receiver Oper-
ating Characteristic) of 0.70 (95% CI: 0.606e0.788,
p Z 0.009). In the univariate analysis model, age at diag-
nosis of BE ( 57 years; OR Z 14.4, 95% CI Z 1.88e110.6,
pZ 0.01), dysphagia as an EGD indication (ORZ 16.4, 95%
CI Z 5.21e51.7, p Z 0.001), and reflux esophagitis
(OR Z 0.27, 95% CI Z 0.09e0.81, p Z 0.019) were risk
factors for the development of EAC (Table 2). In the
multivariate analysis model, age at diagnosis of BE ( 57
years; OR Z 33.9, 95% CI Z 3.54e324.3, p Z 0.002) and
dysphagia as an EGD indication (OR Z 43.5, 95%
CIZ 9.56e198.4, p < 0.001) were independent risk factors
for the development of EAC (Table 2).Discussion
This retrospective study analyzed patients with histologi-
cally confirmed BE and revealed that being male, old age,
and alarm symptoms (especially dysphagia) are the clinical
characteristics of a BE patient with EAC.
The epidemiology data of BE prevalence in Taiwan are
limited and diverse. Lee et al’s [14] analysis of 4600
consecutive health check-up participants revealed a prev-
alence of 0.3%. In another study among 19,812 participants
receiving an endoscopy during a health examination, the
prevalence of ESEM and histologically confirmed BE were
0.28% and 0.06%, respectively [15]. In a previous study, 13
BE cases were found in 736 consecutive patients undergoing
endoscopy for a variety of GI symptoms, with a prevalence
of 1.8% [16], similar to the findings reported by Yeh et al
[17]. Based on the standardized protocol with random four-Table 2 Univariate and multivariate analysis: comparison be
esophageal adenocarcinoma (EAC).
Variable Univariate analysis
Odds Ratio (95%)
Age > 57 y 14.4 (1.88e110.6)
Dysphagia 16.4 (5.21e51.7)
Reflux esophagitis 0.27 (0.09e0.81)
Alcohol 2.84 (0.98e8.21)quadrant endoscopic biopsy, Chang et al [18] revealed that
the prevalence of BE among patients who had a referral
endoscopy, screening endoscopy, and overall was 1.06%,
0.35%, and 0.85%, respectively.
Sex differences have been observed in some esophageal
diseases and the reasons for such differences still require
further study. The incidence rate of GERD is similar be-
tween men and women [19]. However, the incidence rate
of BE, EAC, or BE-associated EAC is higher in men than in
women [2,20e23]. One meta-analysis of cohort studies
showed that the risk of BE among men is two-fold higher
than for women [23]. Edgren et al [20] reported that being
male was a risk factor for esophageal and junctional
adenocarcinoma by seven-fold. One nationwide cohort
study showed that high-grade dysplasia and EAC in the BE
population have a 2:1 male predominance (OR: 2.01; 95%
CI Z 1.68e2.60) [2].
Several investigations have identified the clinical fea-
tures and characteristics of patients with esophageal
adenocarcinoma, including being male, the presence of BE,
gastroesophageal reflux, central obesity [24], decreasing
prevalence of H. pylori infection, hiatal hernia, and low
fruit and vegetable consumption [2,4,22,25,26]. One meta-
analysis study revealed the symptoms of GERD increased
the odds of developing EAC by five-fold to seven-fold [21].
Although patients with BE have a high relative risk of
developing adenocarcinoma of the esophagus (30e125
times higher risk than the general population), their abso-
lute risk is low. The risk of developing EAC for patients with
BE is approximately 0.12e0.5% per year [4]. It is important
to identify the clinical characteristics of patients who have
BE-associated EAC and to commence endoscopic surveil-
lance for patients with a high risk of BE-associated EAC
(such as male sex) before obvious alarm symptoms occur.
In our study, 54.4% of the patients diagnosed with BE
underwent EGD due to typical reflux symptoms. The
severity of reflux esophagitis in most of these people was
classified as L A grade A or B. As in previous reports, there
was a strong association between chronic symptomatic
gastroesophageal reflux and BE [22,27e29]. The reflux of
gastroduodenal contents into the esophagus is considered
to be a risk factor for carcinogenesis due to chronic
esophageal injury.
In our endoscopic findings for BE-associated EAC,
polypoid lesions were found in 86.7% (13/15) of the patients
compared to ulcerative lesions in only 13.3% of patients.
Dysphagia, gastroesophageal bleeding, or body weight loss
were common presentations of BE-associated adenocarci-
noma in this population. Our findings are in agreement with
the report by Gatenby et al [30]. It was concluded thattween Barrett’s esophagus (BE) patients with and without
Multivariate analysis
p Odds Ratio (95%) p
0.010 33.9 (3.54e324.3) 0.002
0.001 43.5 (9.56e198.4) < 0.001
0.019
0.054
Barrett’s esophagus and risk of esophageal adenocarcinoma 139there were strong associations between the symptoms of
dysphagia/odynophagia/weight loss and the development
of high-grade dysplasia and EAC [30]. A similar study also
reported that obvious lumps or nodules located endoscop-
ically suggest that a more advanced lesion with invasion
may be present [31e33].
Our observations also discovered that all BE-associated
adenocarcinoma were men with an older mean age than the
BE population. Male sex and older age were identified as
important independent risk factors for progression to high-
grade dysplasia and EAC [2,21,34].
There are some limitations to the present study. It is
possible that the number of BE patients has been under-
estimated because endoscopically suspected esophageal
metaplasia may not have been routinely biopsied. This may
explain why the portion of the BE population associated
with EAC was higher in our study population (3.4%).
Nonetheless, this study also has several important dis-
tinctions. First, the characteristics and risk of esophageal
malignancy in the BE population became an important
clinical issue. Unquestionably, endoscopic surveillance is
important in detecting BE and associated malignancies for
such BE populations with dysplasia [35,36]. Identifying and
focusing on high-risk patients in the general population
would bring cost benefits for the current health care sys-
tem. Second, current follow-up endoscopic BE surveillance
for nondysplasia, low-grade dysplasia, and high-grade
dysplasia were done every 3 years, 1 year, and 3 months,
respectively [35]. In patients with BE and adenocarcinoma
concurrently, most do not have typical reflux symptoms or
erosive esophagitis, but present with almost alarm symp-
toms. Lump symptoms would be recognized by the patients
themselves, and further endoscopic examination usually
showed visible lumps or nodules that could be considered a
more advanced lesion with invasion [33,37]. Therefore, for
these high-risk patients, it was important to detect EAC at
an early stage.
In conclusion, our study found that BE-associated EAC
mostly occurred in older men. In the group with BE-
associated EAC, most of them were discovered due to
alarm symptoms and meanwhile EAC had already devel-
oped. Further prospective study is needed to stratify the
risk of disease progression in BE patients.Conflicts of interest
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